FCA
ALNY icon

FinTrust Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

FinTrust Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$4.13K Hold
15
– – ﹤0.01% 1125
2024
Q2 		$3.65K Buy
+15
New +$2.37K ﹤0.01% 1109

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FinTrust Capital Advisors's ALNY Position: Q3 2024 in Review

FinTrust Capital Advisors held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2024 at 15 shares worth $4.13K. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

FinTrust Capital Advisors first reported a position in ALNY in Q2 2024 and has held it in 2 quarters since. 566 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • FinTrust Capital Advisors held 15 shares of Alnylam Pharmaceuticals worth $4.13K as of Q3 2024.
  • FinTrust Capital Advisors left its Alnylam Pharmaceuticals share count unchanged in Q3 2024.
  • Alnylam Pharmaceuticals made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1125 holding.
  • FinTrust Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • 566 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.